Literature DB >> 9506953

A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities.

V Joukov1, V Kumar, T Sorsa, E Arighi, H Weich, O Saksela, K Alitalo.   

Abstract

The vascular endothelial growth factor (VEGF) and the VEGF-C promote growth of blood vessels and lymphatic vessels, respectively. VEGF activates the endothelial VEGF receptors (VEGFR) 1 and 2, and VEGF-C activates VEGFR-3 and VEGFR-2. Both VEGF and VEGF-C are also potent vascular permeability factors. Here we have analyzed the receptor binding and activating properties of several cysteine mutants of VEGF-C including those (Cys156 and Cys165), which in other platelet-derived growth factor/VEGF family members mediate interchain disulfide bonding. Surprisingly, we found that the recombinant mature VEGF-C in which Cys156 was replaced by a Ser residue is a selective agonist of VEGFR-3. This mutant, designated DeltaNDeltaC156S, binds and activates VEGFR-3 but neither binds VEGFR-2 nor activates its autophosphorylation or downstream signaling to the ERK/MAPK pathway. Unlike VEGF-C, DeltaNDeltaC156S neither induces vascular permeability in vivo nor stimulates migration of bovine capillary endothelial cells in culture. These data point out the critical role of VEGFR-2-mediated signal transduction for the vascular permeability activity of VEGF-C and strongly suggest that the redundant biological effects of VEGF and VEGF-C depend on binding and activation of VEGFR-2. The DeltaNDeltaC156S mutant may provide a valuable tool for the analysis of VEGF-C effects mediated selectively via VEGFR-3. The ability of DeltaNDeltaC156S to form homodimers also emphasizes differences in the structural requirements for VEGF and VEGF-C dimerization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506953     DOI: 10.1074/jbc.273.12.6599

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Authors:  Simon Schwager; Silvana Renner; Teresa Hemmerle; Sinem Karaman; Steven T Proulx; Roman Fetz; Alexandra Michaela Golding-Ochsenbein; Philipp Probst; Cornelia Halin; Dario Neri; Michael Detmar
Journal:  JCI Insight       Date:  2018-12-06

3.  Molecular characterization of lymphatic endothelial cells.

Authors:  Simona Podgrabinska; Pascal Braun; Paula Velasco; Bryan Kloos; Michael S Pepper; Mihaela Skobe
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-22       Impact factor: 11.205

4.  Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span.

Authors:  Riccardo E Nisato; Jillian A Harrison; Raphaele Buser; Lelio Orci; Chris Rinsch; Roberto Montesano; Philippe Dupraz; Michael S Pepper
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

5.  VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism.

Authors:  Jerome W Breslin; Sarah Y Yuan; Mack H Wu
Journal:  Lymphat Res Biol       Date:  2007       Impact factor: 2.589

6.  NFATc1 regulates lymphatic endothelial development.

Authors:  Rishikesh M Kulkarni; James M Greenberg; Ann L Akeson
Journal:  Mech Dev       Date:  2009-02-20       Impact factor: 1.882

7.  Non-invasive dynamic near-infrared imaging and quantification of vascular leakage in vivo.

Authors:  Steven T Proulx; Paola Luciani; Annamari Alitalo; Viviane Mumprecht; Ailsa J Christiansen; Reto Huggenberger; Jean-Christophe Leroux; Michael Detmar
Journal:  Angiogenesis       Date:  2013-01-17       Impact factor: 9.596

Review 8.  Beyond a Passive Conduit: Implications of Lymphatic Biology for Kidney Diseases.

Authors:  Daniyal J Jafree; David A Long
Journal:  J Am Soc Nephrol       Date:  2020-04-15       Impact factor: 10.121

9.  Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Authors:  LouJin Song; Xian Chen; Terri A Swanson; Brianna LaViolette; Jincheng Pang; Teresa Cunio; Michael W Nagle; Shoh Asano; Katherine Hales; Arun Shipstone; Hanna Sobon; Sabra D Al-Harthy; Youngwook Ahn; Steven Kreuser; Andrew Robertson; Casey Ritenour; Frank Voigt; Magalie Boucher; Furong Sun; William C Sessa; Rachel J Roth Flach
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140

Review 10.  Molecular mechanisms of lymphangiogenesis.

Authors:  Meiko Takahashi; Takanobu Yoshimoto; Hajime Kubo
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.